par Ribrag, Vincent;Tilly, Hervé;Casasnovas, Olivier;Bosly, André;Bouabdallah, Reda;Delarue, Richard;Boue, François;Bron, Dominique ;Feugier, Pierre;Haioun, Corinne;Offner, Firtz;Coiffier, Bertrand
Référence European journal of cancer, 49, 4, page (904-910)
Publication Publié, 2013-03
Référence European journal of cancer, 49, 4, page (904-910)
Publication Publié, 2013-03
Article révisé par les pairs
Titre: |
|
Auteur: | Ribrag, Vincent; Tilly, Hervé; Casasnovas, Olivier; Bosly, André; Bouabdallah, Reda; Delarue, Richard; Boue, François; Bron, Dominique; Feugier, Pierre; Haioun, Corinne; Offner, Firtz; Coiffier, Bertrand |
Informations sur la publication: | European journal of cancer, 49, 4, page (904-910) |
Statut de publication: | Publié, 2013-03 |
Sujet CREF: | Cancérologie |
Mots-clés: | Bortezomib |
Clinical trial | |
Follicular lymphoma | |
Phase II | |
Salvage therapy | |
MeSH keywords: | Adult |
Aged | |
Antineoplastic Agents -- therapeutic use | |
Boronic Acids -- therapeutic use | |
Cohort Studies | |
Drug Resistance, Neoplasm -- drug effects | |
Female | |
Follow-Up Studies | |
Humans | |
Lymphoma, Follicular -- drug therapy -- mortality -- pathology | |
Male | |
Maximum Tolerated Dose | |
Middle Aged | |
Neoplasm Grading | |
Neoplasm Recurrence, Local -- drug therapy -- mortality -- pathology | |
Prognosis | |
Pyrazines -- therapeutic use | |
Salvage Therapy | |
Survival Rate | |
Note générale: | SCOPUS: ar.j |
Langue: | Anglais |
Identificateurs: | urn:issn:0959-8049 |
info:doi/10.1016/j.ejca.2012.11.015 | |
info:pii/S0959804912009112 | |
info:scp/84873718393 | |
info:pmid/23273434 |